Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide

International Journal of Dermatology

Volumn 51, Issue 3, 2012, Pages 345-348

  Wan, Pengjie ^a   Zhao, Xiaoqing ^a   Hunasehally, Ranganna Y P ^b   Shi, Ruofei ^a   Zheng, Jie ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b PRINCESS OF WALES HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; RHEUMATOID FACTOR; THALIDOMIDE; THIAMAZOLE;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER; FOLLOW UP; HAND PALM; HISTIOCYTE; HUMAN; HYPERTHYROIDISM; LEG; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; PANNICULITIS; SKIN BIOPSY; SKIN NODULE; WRIST;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; ERYTHEMA NODOSUM; FEMALE; HUMANS; HYPERTHYROIDISM; IMMUNOLOGIC FACTORS; MIDDLE AGED; PROPYLTHIOURACIL; THALIDOMIDE;

EID: 84863128318     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05135.x     Document Type: Article

References (36)

1. Gao Y, Zhao MH. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 2009; 14: 33-41.
2. Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 2005; 7: 191-192.
3. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996; 15: 53-63.
4. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-652.
5. Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001; 54: 651-654.
6. Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000; 85: 4270-4273.
7. Yarman S, Sandalci O, Tanakol R, et al. Propylthiouracil-induced cutaneous vasculitis. Int J Clin Pharmacol Ther 1997; 35: 282-286.
8. Harper L, Cockwell P, Savage CO. Case of propylthiouracil-induced ANCA associated small vessel vasculitis. Nephrol Dial Transplant 1998; 13: 455-458.
9. Yu F, Zhao MH, Zhang YK, et al. Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity. Clin Exp Immunol 2005; 139: 569-574.
10. Helfgott SM, Smith RN. A 21-year-old man with arthritis during treatment for hyperthyroidism. N Engl J Med 2002; 347: 122-130.
11. Keren G, Lehr V, Boichis H. Erythema nodosum related to propylthiouracil treatment for thyrotoxicosis. Isr J Med Sci 1985; 21: 62-63.
12. Ozkok A, Salman S, Agan M, et al. Propylthiouracil induced anti-neutrophil cytoplasmic antibody-associated vasculitis with bone marrow plasmacytosis and granulocytopenia. Chin Med J (Engl) 2009; 122: 1112-1114.
13. Otsuka S, Kinebuchi A, Tabata H, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy. Br J Dermatol 2000; 142: 828-830.
14. Chastain MA, Russo GG, Boh EE, et al. Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature. J Am Acad Dermatol 1999; 41: 757-764.
15. Pasquet F, Pavic M, Mounier C, et al. Antineutrophil cytoplasmic antibody associated vasculitis: an uncommon side effect of propylthiouracil. Rev Med Interne 2009; 30: 882-885.
16. Batchelor N, Holley A. A fatal case of propylthiouracil-induced ANCA-positive vasculitis. MedGenMed 2006; 8: 10.
17. Aycan Z, Arhan E, Cetinkaya E, et al. Propylthiouracil-induced hypersensitivity syndrome. Turk J Pediatr 2006; 48: 162-165.
18. Sheen YS, Chu CY, Yu HS. Antineutrophil cytoplasmic antibody-positive cutaneous leukocytoclastic vasculitis associated with propylthiouracil therapy. Arch Dermatol 2006; 142: 879-880.
19. Hidalgo VS, Silva AP, Undurraga SF, et al. Antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis associated to the use of propylthiouracil. Report of four cases. Rev Med Chil 2006; 134: 475-480.
20. Wisniewski P, Lewczuk A, Czaplinska-Kalas H, et al. Anti neutrophil cytoplasmatic antibodies-positive vasculitis as a complication of hyperthyreosis treatment with propylthiouracil. Pol Merkur Lekarski 2005; 19: 674-677.
21. Jacobs EM, Hartkamp A, Kaasjager HA. PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies. Neth J Med 2003; 61: 296-299.
22. Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, et al. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai 2002; 85(Suppl 4): S1295-S1301.
23. Xu X, Zhao M, Zhang Y, et al. Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: a report of 4 cases and literature review. Zhonghua Nei Ke Za Zhi 2002; 41: 404-407.
24. Kudoh Y, Kuroda S, Shimamoto K, Iimura O. Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies. Clin Nephrol 1997; 48: 41-43.
25. Sorribes MM, Welinder NR, Stangerup SE. Anti-neutrophil cytoplasmic antibody-associated mucocutaneous allergic vasculitis with oral manifestations caused by propylthiouracil. J Laryngol Otol 1999; 113: 477-479.
26. Baker-LePain JC, Farmer-Boatwright MK, Dooley MA. Concurrent Takayasu's arteritis and antineutrophil cytoplasmic antibody-related glomerulonephritis related to use of propylthiouracil. J Rheumatol 2009; 36: 1552-1554.
27. Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology 2004; 208: 339-341.
28. Darben T, Savige J, Prentice R, et al. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol 1999; 40: 144-146.
29. Boulenger-Vazel A, Kupfer-Bessaguet I, Gouedard C, et al. Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies). Ann Dermatol Venereol 2005; 132: 27-31.
30. Gungor K, Gonen S, Kisakol G, et al. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest 2006; 29: 575-576.
31. Miller RM, Darben TA, Nedwich J, Savige J. Propylthiouracil-induced antineutrophil cytoplasmic antibodies in a patient with Graves' disease and a neutrophilic dermatosis. Br J Dermatol 1999; 141: 943-944.
32. Darne S, Natarajan S, Blasdale C. Do antineutrophil cytoplasmic antibodies (ANCA) play a key role in neutrophilic dermatoses? A case of propylthiouracil-induced neutrophilic dermatosis with positive perinuclear ANCA Clin Exp Dermatol 2010; 35: 406-408.
33. Wang LH, Tsai MJ, Tsai WY, et al. Propylthiouracil-induced antineutrophil cytoplasm antibody-positive anaphylactoid purpura-like vasculitis-a case report. J Formos Med Assoc 2000; 99: 642-645.
34. Saito M, Nakamura K, Kaneko F. Lichenoid drug eruption of nails induced by propylthiouracil. J Dermatol 2007; 34: 696-698.
35. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28: 577-586.
36. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487-495.